Thymulin Analog (PAT) vs Thymalin — Peptide Comparison

At a Glance

Quickcomparison

Dose Range

Thymulin Analog (PAT)

1 mcg–50 mcg mcg

Thymalin

5–10 mg

Frequency

Once daily

Administration

Intraperitoneal injection

Intramuscular injection

Cycle Length

Ongoing/indefinite

4-6 weeks

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Strong human trials (Phase 3 or FDA approved)

Limited human trials

Efficacy

Benefitratings

Pain Relief

Anti-Inflammatory

Neuroprotection

Immune Restoration

Longevity Support

Disease Prevention

Technical Data

Compoundspecifications

Molecular Formula

C37H62N12O15

Molecular Weight

858.9 Da

Half-Life

Effects peak at 1-2 hours; diminish by 3-4 hours post-single dose

Bioavailability

Effective via intraperitoneal and intracerebroventricular routes in preclinical models

CAS Number

Not assigned

Complex mixture; active dipeptide EW: C16H19N3O5

Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da

Not precisely characterized for complex; immune effects persist weeks post-administration

High via intramuscular or subcutaneous injection

63958-90-7

Protocols

Dosingtiers

standard

5-10 mg reconstituted in saline

5-10 day course, often repeated every 6 months

Reflects the Russian clinical course used in immune-restoration and gerontology protocols, typically 10 mg IM daily for 5-10 days [1].

advanced

10 mg

Up to 20 day course, repeated every 6 months

Subcutaneous administration is used in community practice at the same 10 mg daily dosing; longer 20-day courses are described for cyclical immune support [1].

Applications

Bestsuited for

Neuropathic pain research

Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-inflammatory therapy development

Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Novel analgesic mechanism investigation

Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Cytokine-mediated pain pathway studies

Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Aging Adults Seeking Immune Support

Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.

Longevity and Anti-Aging Protocols

Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.

Seasonal Illness Prevention

Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Safety Profile

Sideeffects

Common

Injection Site Reaction

Transient Immune Modulation

Mild Sedation

Short Duration of Action

Uncommon

Potential Immune Suppression

CNS Effects with Central Administration

Serious

Unintended Immune Stimulation

No side effects in most patients

Mild injection site reaction

Transient low-grade fever

Mild flu-like symptoms

Temporary headache

Severe allergic reaction

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.

Contraindications

xNot approved for human use

xPotential immune modulation concerns with chronic use

xUnknown drug-drug interactions

xPregnancy and lactation (insufficient safety data)

Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

xActive thymic tumors or malignancies

xKnown hypersensitivity to animal-derived peptide products

xPregnancy and breastfeeding (insufficient safety data)

xSevere uncontrolled autoimmune disease without medical supervision

Decision Guide

Which isright for you?

Choose Thymulin Analog (PAT) if...

Neuropathic pain research

Anti-inflammatory therapy development

Novel analgesic mechanism investigation

Cytokine-mediated pain pathway studies

Choose Thymalin if...

Immune system restoration in aging adults

Longevity and healthy aging support

Reducing infection frequency and severity

Multi-system health optimization